[1]阮兴秋.中医药治疗晚期肺腺癌的生存分析[J].医学信息,2020,33(12):62-66.[doi:10.3969/j.issn.1006-1959.2020.12.019]
　RUAN Xing-qiu.Survival Analysis of Traditional Chinese Medicinefor Advanced Lung Adenocarcinoma[J].Medical Information,2020,33(12):62-66.[doi:10.3969/j.issn.1006-1959.2020.12.019]
点击复制

中医药治疗晚期肺腺癌的生存分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年12期
页码:
62-66
栏目:
论著
出版日期:
2020-06-15

文章信息/Info

Title:
Survival Analysis of Traditional Chinese Medicinefor Advanced Lung Adenocarcinoma
文章编号:
1006-1959（2020）12-0062-05
作者:
阮兴秋
（玉林市红十字会医院中西医结合科，广西 玉林 537001）
Author(s):
RUAN Xing-qiu
(Department of Integrated Traditional Chinese and Western Medicine,Yulin Red Cross Hospital,Yulin 537001,Guangxi,China)
关键词:
晚期肺腺癌; 中医药; 生存分析; 预后因素
Keywords:
Advanced lung adenocarcinoma; Traditional Chinese medicine; Survival analysis; Prognostic factors
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2020.12.019
文献标志码:
A
摘要:
目的 观察中医药干预治疗晚期肺腺癌的效果及对患者生存期的影响。方法 回顾性分析2013年1月~2017年12月广西玉林市红十字会医院收治的80例晚期肺腺癌患者的临床资料，根据中医药参与治疗程度分为中医组（化疗、放疗、靶向治疗中任意一项+中成药或者中药汤剂治疗）和西医组（化疗、放疗及靶向药物），比较两组晚期肺腺癌患者的生存情况，采用Kaplan-Meirer法进行生存分析和Cox模型进行预后影响因素分析。结果 80例患者6个月、1、2、3、5年生存率分别为79.30%、52.51%、18.33%、2.73%、0，中位生存时间为370 d；中医组、西医组中位生存期分别为512 d、270 d，6个月、1、2、3、5年生存率分别为87.51%、65.23%、27.14%、15.22%、3.47%，65.12%、37.53%、16.25%、0、0。单因素分析显示，两组生存期比较，差异有统计学意义（P＜0.05）。Cox多因素分析显示，血行转移、放射治疗、中医证型是影响晚期肺腺癌患者死亡的独立预后因素，根据相对风险系数及回归系数可知，血行转移是独立危险因素（B=1.625，RR=5.216），放射治疗（B=-0.915，RR=0.400）及中医证型（B=-0.287，RR=0.751）为独立保护因素。结论 中医药干预治疗能有效延长晚期肺腺癌患者的中位生存期，其中放疗及中医证型既是晚期肺腺癌预后的独立影响因素，又是独立保护因素，而血行转移则为独立危险因素。
Abstract:
Objective To observe the effect of traditional Chinese medicine intervention in the treatment of advanced lung adenocarcinoma and its impact on the survival time of patients.Methods Retrospectively analyzed the clinical data of 80 patients with advanced lung adenocarcinoma admitted to the Red Cross Hospital of Yulin City, Guangxi from January 2013 to December 2017, and divided them into traditional Chinese medicine groups (chemotherapy, radiotherapy, targeted therapy) according to the degree of participation of traditional Chinese medicine Any one of the above + Chinese patent medicine or Chinese medicine decoction) and the Western medicine group (chemotherapy, radiotherapy and targeted drugs), compare the survival of the two groups of patients with advanced lung adenocarcinoma, use Kaplan-Meirer method for survival analysis and Cox model Analysis of prognostic factors.Results The 6-month, 1, 2, 3, and 5-year survival rates of 80 patients were 79.30%, 52.51%, 18.33%, 2.73%, and 0, respectively. The median survival time was 370 d; the median survival time of the Chinese medicine group and the Western medicine group 512 d, 270 d, 6-month, 1, 2, 3, 5-year survival rates were 87.51%, 65.23%, 27.14%, 15.22%, 3.47%, 65.12%, 37.53%, 16.25%, 0, 0. Univariate analysis showed that the difference in survival between the two groups was statistically significant (P<0.05). Cox multivariate analysis showed that blood metastasis, radiotherapy, and TCM syndromes are independent prognostic factors that affect the death of patients with advanced lung adenocarcinoma. According to the relative risk coefficient and regression coefficient, blood metastasis is an independent risk factor (B=1.625, RR= 5.216), radiotherapy (B=-0.915, RR=0.400) and TCM syndrome type (B=-0.287, RR=0.751) are independent protective factors.Conclusion Interventional treatment with traditional Chinese medicine can effectively prolong the median survival time of patients with advanced lung adenocarcinoma. Among them, radiotherapy and TCM syndromes are both independent influencing factors and prognostic factors for advanced lung adenocarcinoma, and blood metastasis is an independent risk factor.

参考文献/References:

[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China2015[J].Ca A Cancer Journal for Clinicians,2016,66(2):115-132.[2]Tsubokawa N,Mimae T,Sasada S,et al.Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma[J],Eur J Cardiothorac Surg,2016,49(1):293-299．[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:208-211.[4]Ⅵsbal AL,Leiglll NB,Feld R,et al.Adjuvant chemomerapy for eally-stae non-small cell lung cancer[J].Chest,2005,128(4):2933-2943．[5]吴一龙.免疫治疗:混沌、曙光、探索[J].循证医学,2017,17(4):193-198.[6]叶译楚.吴一龙教授回顾ESMO肺癌研究亮点--靶向与免疫继续引领潮流[N].中国医学论坛报,2017-09-18(3).[7]周岱翰,林丽珠,田华琴,等.益气化痰法为主中医药治疗方案对老年非小细胞肺癌中位生存期的影响：一项多中心、前瞻性临床队列研究[J].世界中医药,2014,9(7):833-838.

相似文献/References:

[1]车启富,何丽杰.中医辨证治疗老年不稳定型心绞痛的效果观察[J].医学信息,2018,31(02):141.[doi:10.3969/j.issn.1006-1959.2018.02.053]
[2]夏能能,任 薇,杜建平,等.1953~2016年中医药治疗高血压领域研究热点分析[J].医学信息,2018,31(04):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
　XIA Neng-neng,REN Wei,DU Jian-ping,et al.Analysis of Hot Spots in the Research of Traditional Chinese Medicine in Treating Hypertension from 1953 to 2016[J].Medical Information,2018,31(12):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
[3]黄 婷,李绍旦,高 路,等.中医药防治心肌缺血再灌注损伤的研究进展[J].医学信息,2018,31(04):31.[doi:10.3969/j.issn.1006-1959.2018.04.011]
　HUANG Ting,LI Shao-dan,GAO Lu,et al.Research Progress on the Prevention and Treatment of Myocardial Ischemia and Reperfusion Injury by Traditional Chinese Medicine[J].Medical Information,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.04.011]
[4]杨少岩.中医药治疗中风后抑郁的研究[J].医学信息,2018,31(11):57.[doi:10.3969/j.issn.1006-1959.2018.11.018]
　YANG Shao-yan.Study on Treatment of Post-stroke Depression with Traditional Chinese Medicine[J].Medical Information,2018,31(12):57.[doi:10.3969/j.issn.1006-1959.2018.11.018]
[5]贺 佳,杜建强,聂 斌,等.智能问答系统在医学领域的应用研究[J].医学信息,2018,31(14):16.[doi:10.3969/j.issn.1006-1959.2018.14.007]
　HE Jia,DU Jian-qiang,NIE Bin,et al.Research on the Application of Intelligent Question-answering System in Medical Field[J].Medical Information,2018,31(12):16.[doi:10.3969/j.issn.1006-1959.2018.14.007]
[6]仇璐娜.慢性疲劳综合征的中医研究[J].医学信息,2018,31(21):48.[doi:10.3969/j.issn.1006-1959.2018.21.014]
　QIU Lu-na.TCM Research on Chronic Fatigue Syndrome[J].Medical Information,2018,31(12):48.[doi:10.3969/j.issn.1006-1959.2018.21.014]
[7]李 伟,陈素华.妊娠期人巨细胞病毒感染的中医药研究进展[J].医学信息,2019,32(01):37.[doi:10.3969/j.issn.1006-1959.2019.01.013]
　LI Wei,CHEN Su-hua.Advances in Research on Traditional Chinese Medicine for Human Cytomegalovirus Infection during Pregnancy[J].Medical Information,2019,32(12):37.[doi:10.3969/j.issn.1006-1959.2019.01.013]
[8]尚先宝.中医药防治老年骨质疏松骨折研究进展[J].医学信息,2019,32(11):45.[doi:10.3969/j.issn.1006-1959.2019.11.013]
　SHANG Xian-bao.Advances in Research on Prevention and Treatment of Senile Osteoporotic Fractures with Traditional Chinese Medicine[J].Medical Information,2019,32(12):45.[doi:10.3969/j.issn.1006-1959.2019.11.013]
[9]孙 鹏.腰椎椎管狭窄症的中医药治疗研究[J].医学信息,2019,32(17):57.[doi:10.3969/j.issn.1006-1959.2019.17.018]
　SUN Peng.Chinese Medicine Treatment of Lumbar Spinal Stenosis[J].Medical Information,2019,32(12):57.[doi:10.3969/j.issn.1006-1959.2019.17.018]
[10]徐忆芳,罗秀丽.基于数据挖掘的罗秀丽教授治疗三阴性乳腺癌的临床经验研究[J].医学信息,2019,32(20):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
　XU Yi-fang,LUO Xiu-li.Professor Luo Xiuli's Clinical Experience in Treating Triple-negative Breast Cancer Based on Data Mining[J].Medical Information,2019,32(12):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]

更新日期/Last Update: 1900-01-01